January 5, 2023
1 minute read
Athira Pharma Inc. announced in a press release several clinical trials for the treatment of Alzheimer’s disease, Parkinson’s disease and ALS, a biopharmaceutical company, in 2023.
Athira President and CEO Dr. Mark Lytton, mentioned in the release.
Athira is currently testing candidate ATH-1017, or fosgonimeton, a small molecule designed to increase the activity of hepatocyte growth factor (HGF) and its receptor MET, which protects neural networks. and may be repaired, the release said.
The company expects to complete enrollment of a Phase 2/3 trial in patients with mild to moderate AD to compare the effects of phosgonimetone to placebo in mid-2023. Topline data he is due in early 2024.
“An independent, unblinded interim efficacy and futility analysis of the Phase 2/3 trial reduces the risks of the phosgonimetone program and supports the potential clinical benefit of phosgonimetone treatment, demonstrating this promising We believe it underscores the rationale for the continued development of potentially novel therapeutics,” said Lytton.
In addition, Athira enrolled 28 patients with PD dementia or dementia with Lewy bodies to participate in a Phase 2 trial of phosgonimetone.
“Recently published compelling preclinical data on the potential of phosgonimetone to improve motor function in Parkinson’s disease highlight [Athira] We seek to evaluate study designs to further explore its potential in this complex disease,” said the release.
Athira will also evaluate candidate ATH-1020, an orally available therapeutic agent designed to enhance the HGF/MET system and a potential therapeutic candidate for neuropathic pain and neurodegenerative diseases. In a Phase 1 trial of ATH-1020, the candidate showed a favorable safety profile and was well tolerated in healthy volunteers.
Athira’s final candidate, ATH-1105, is a small molecule positive modulator of the HGF/MET system and a potential candidate for ALS. Preclinical data will be presented in December 2022. The company plans to submit an investigational drug application to the FDA and begin human trials in 2023.
“Importantly, we will continue to explore the potential of phosgonimetone in Alzheimer’s disease, Parkinson’s dementia, dementia with Lewy bodies, and advance other programs such as ATH-1105 in ALS to major inflection points. It’s about having a strong balance sheet that can do that,” Lytton said.